中国医药：盐酸林可霉素注射液通过一致性评价

Core Viewpoint - The announcement highlights that Tianfang Pharmaceutical, a subsidiary of China Pharmaceutical, has successfully passed the consistency evaluation for the quality and efficacy of its Lincomycin Hydrochloride Injection, which is expected to enhance its market competitiveness and expand market share [1] Group 1: Product Development - Tianfang Pharmaceutical's Lincomycin Hydrochloride Injection received acceptance for consistency evaluation by the National Medical Products Administration in July 2024 [1] - The company has invested approximately 6.08 million RMB (about 0.608 million) in the development of this product as of the announcement date [1] Group 2: Market Potential - The domestic sales revenue for public hospitals and grassroots medical terminals in 2024 is projected to be around 77 million RMB (approximately 0.77 billion) [1] - Tianfang Pharmaceutical's sales revenue for this product is approximately 15.32 million RMB (about 1.532 million) [1] Group 3: Competitive Advantage - Passing the consistency evaluation is expected to improve the market competitiveness of the Lincomycin Hydrochloride Injection, allowing for further market share expansion [1]